key: cord-0789116-kq1ffmx1
authors: Mirgh, Sumeet; Gokarn, Anant; Punatar, Sachin; Chichra, Akanksha; Singh, Anuj; Rajendra, Akhil; Babu Goli, Vasu; Trivedi, Bhakti; Joshi, Amit; Patkar, Nikhil; Tembhare, Prashant; Subramanian, P. G.; Shetty, Nitin; Chavan, Preeti; Bhat, Vivek; Gupta, Sudeep; Khattry, Navin
title: Clinical course of severe COVID19 treated with tocilizumab and antivirals post‐allogeneic stem cell transplant with extensive chronic GVHD
date: 2021-02-18
journal: Transpl Infect Dis
DOI: 10.1111/tid.13576
sha: 90917226568fecb08714af86b3368ad8dce3aaad
doc_id: 789116
cord_uid: kq1ffmx1

Recipients of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are an immunocompromised group who are likely to develop severe complications and mortality because of coronavirus disease 2019 (COVID‐19). We report here a 61‐year‐old male patient of primary myelofibrosis who underwent an allo‐HSCT 6 years earlier, had chronic graft‐versus‐host disease (cGVHD) involving the liver, lung, eyes, and skin, (with recurrent episodes of pulmonary infections) who developed severe COVID‐19. The patient was treated with tocilizumab, and a combination of lopinavir/ritonavir, ribavirin, interferon‐β1b. He was discharged after 31 days with full recovery. Tocilizumab, a humanized monoclonal antibody against IL6, has been shown to benefit respiratory manifestations in severe COVID19. However, this is first report, to our knowledge, of its use and benefit in a post HSCT recipient.

In May 2020, at the age of 61 years, he presented to the emergency room with a 3-day history of high-grade fever, sore throat, and anorexia. On admission, he was febrile (103F), hemodynamically stable with normal oxygen saturation and clear lungs. Broad spectrum antibiotics and intravenous hydration were initiated. Baseline investigations revealed a normal hemogram with lymphopenia [Absolute lymphocyte count(ALC)-1.12 × 10 9 /L (10% of differential), Neutrophil/lymphocyte ratio-6.4], normal liver function tests, elevated CRP (11 mg%) [normal reference interval (RI): 0-0.33 mg%], procalcitonin (11.3 ng/mL) (normal: <0.5 ng/mL) and creatinine (1.9 mg/dL, eGFR: 42 mL/min). Coagulation parameters (PT/PTT), including D-Dimer (<200 ng/mL) were normal with elevated fibrinogen (1100 mg/dL) (normal RI-150-400 mg/dL). His SARS-CoV2 RT-PCR was positive and at the time of hospitalization, he had mild COVID19 (score 5), as per ordinal scale. 5 In view of persistent fever, he was started on triple combination of lopinavir-ritonavir(LPV/r) 12 However, in severe COVID19, there was no added benefit of 10-day remdesivir over a 5-day course. 5 At the time of our patient, remdesivir was not available in India. Hence, we used the tri- in severe cases and from its approval for mitigating the CRS induced by chimeric antigen receptor-T cell therapy. 15 TCZ has been used in severe COVID19, including in a fraction of patients with chronic kidney disease. 8 Similar to our case (Figures 1 and 2) , they have also shown that TCZ produces rapid improvement in inflammatory markers and radiological parameters. 8 

Our report points out the fact that use of TCZ in an immunocompromised patient who has significant comorbities because of his posttransplant complications can lead to favorable outcomes.

None.

https://orcid.org/0000-0003-0642-2207

COVID-19 diagnosis and management: a comprehensive review

COVID-19) dashboard. Geneva: World Health Organization

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib

Remdesivir for 5 or 10 days in patients with severe covid-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Interleukin-6 in Covid-19: a systematic review and meta-analysis

Tocilizumab for the treatment of severe coronavirus disease 2019

Neuropsychiatric effects of antiviral drugs

Centre for International Blood and Marrow Transplant Research

The Medical College of Wisconsin, Inc. and the National Marrow Donor Program

Flattening the COVID-19 curve with natural killer cell based immunotherapies

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

The dual nature of type I and type II interferons

). (2020) A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults (ACTT-3). Identifier NCT04492475

Tocilizumab: the key to stop coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Front Med

). (2020) A randomized, doubleblind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with COVID-19 pneumonia. Identifier NCT04372186

COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience

COVID-19 in post-transplant patientsreport of 2 cases

The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19

Attenuated novel SARS coronavirus 2 infection in an allogeneic hematopoietic stem cell transplant patient on ruxolitinib

Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD